GlassScriptPhysician profile
Robert Chance Algar
NPI 1750343729
$4,446.00
in general payments reported to CMS, 2019-2025
51 companies · $929 in 2025
The $929 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $453 · 2020: $476 · 2021: $672 · 2022: $589 · 2023: $492 · 2024: $835 · 2025: $929.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,255 · Education: $1.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,255.32 |
| Education | $1.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $622.34 | 2021-2025 | Ubrelvy, Qulipta, Botox |
| Lilly USA, LLC | $299.50 | 2019-2025 | Amyvid, Kisunla, Emgality |
| Teva Pharmaceuticals USA, INC. | $295.22 | 2019-2024 | Austedo Xr |
| Alexion Pharmaceuticals, INC. | $211.36 | 2019-2025 | Ultomiris |
| Kyowa Kirin, INC. | $167.32 | 2020-2023 | Nourianz |
| Novartis Pharmaceuticals Corporation | $163.40 | 2019-2025 | |
| Neurocrine Biosciences, INC. | $156.92 | 2020-2025 | |
| Allergan, INC. | $148.77 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $145.17 | 2022 | |
| Ucb, INC. | $138.55 | 2019-2024 | Rystiggo |
| Genentech USA, INC. | $124.75 | 2023-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Biogen, INC. | $108.78 | 2019-2024 | Tysabri, Vumerity |
| Merz Pharmaceuticals, LLC | $104.31 | 2023-2025 | Xeomin, Inbrija |
| Amgen INC. | $93.62 | 2024-2025 | Uplizna |
| Argenx US, INC. | $91.98 | 2023-2024 | Vyvgart, Vyvgart Hytrulo |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Algar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.